A compound of Formula or a pharmaceutically acceptable salt, tautomer, stereoisomer, or hydrate, or solvate thereof: wherein a dashed line signifies that a single bond or a double bond can be present, provided that there are two double bonds and three single bonds in the ring comprising A 1, A 2, and A 3; A 1, A 2, and A 3 each independently is C or S or N; provided that one of A 1, A 2, and A 3 is S; R 1 is R 3 is C 2-4 alkyl; and Y is -CN, -Cl, I, -O-R 3, -COOH, -COOR 3, or -CF 3; R 2 is or X is NR'R" or -OR"'; R' is H, C 1-4 alkyl, n-hydroxy C 1-4 alkyl, -SO 2 -R 3, or -CO-R 3; R" is H, -SO 2 -R 5, C 1-4 alkyl optionally substituted with 1 or more R 4, or a ring moiety optionally substituted with R 6 wherein such ring moiety is piperidinyl, cyclohexyl, morpholinyl, thiazolyl, pyrazolyl, pyrrolidinyl, imidazolyl, or phenyl; R'" is H, C 1-4 alkyl, or -CO-R 3 each R 4 is independently H, halo, OH, oxo, =NH, NH 2, -COOH, F, -NHR 3, - N(R 7 R 7),-SO 2 -R 3, -SO 2 -N(R 7 R 7), -N(R 3)-SO 2 -R 3, -COOR 3, -OCO-R 3, -CO-N(R 7 R 7), -N(R 3)-COR 3, C 1-3 alkyl, C 1-3 alkoxy, and a ring moiety optionally substituted with R 6 wherein such ring moiety is piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyrazolyl, imidazolyl, benzimidazolyl, azetidinyl, cyclobutinyl, or phenyl; each R 5 is independently R 4, C 1-4 alkyl, C 3-6 cycloalkyl, or C 1-4 alkyl optionally substituted with 1 or more R 4; each R 6 is independently halo, OH, -NH 2, -NHR 3, -N(R 3 R 3), -COOH, -COOR 3, - NHCO-R 3; each R 6 is independently C 1-4 alkyl or H, or two R 6 taken together with the nitrogen atom to which they are bound form a 4, 5, or 6 membered saturated heterocyclic ring containing 0 or 1 additional heteroatoms where such additional heteroatom is O or N wherein such heterocycle is optionally substituted with -OH, - NH 2, -N(R 3 R 3), n-hydroxy C 1-4 alkyl, -(CH 2) m -COOH, -(CH 2) m -COOR 3; each m is independently 0, 1, 2, or 3, wherein the structure of Formula I is selected from the group consisting of formulas a-i through a-x: a dashed line signifies that a single bond or a double bond can be present, provided that there are two double bonds and three single bonds in the ring comprising A 1, A 2, and A 3; A 1, A 2, and A 3 each independently is C or S or N; provided that one of A 1, A 2, and A 3 is S; R 1 is R 3 is C 2-4 alkyl; and Y is -CN, -Cl, I, -O-R 3, -COOH, -COOR 3, or -CF 3; R 3 is C 2-4 alkyl; and Y is -CN, -Cl, I, -O-R 3, -COOH, -COOR 3, or -CF 3; R 2 is or X is NR'R" or -OR"'; R' is H, C 1-4 alkyl, n-hydroxy C 1-4 alkyl, -SO 2 -R 3, or -CO-R 3; R" is H, -SO 2 -R 5, C 1-4 alkyl optionally substituted with 1 or more R 4, or a ring moiety optionally substituted with R 6 wherein such ring moiety is piperidinyl, cyclohexyl, morpholinyl, thiazolyl, pyrazolyl, pyrrolidinyl, imidazolyl, or phenyl; R'" is H, C 1-4 alkyl, or -CO-R 3 each R 4 is independently H, halo, OH, oxo, =NH, NH 2, -COOH, F, -NHR 3, - N(R 7 R 7),-SO 2 -R 3, -SO 2 -N(R 7 R 7), -N(R 3)-SO 2 -R 3, -COOR 3, -OCO-R 3, -CO-N(R 7 R 7), -N(R 3)-COR 3, C 1-3 alkyl, C 1-3 alkoxy, and a ring moiety optionally substituted with R 6 wherein such ring moiety is piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyrazolyl, imidazolyl, benzimidazolyl, azetidinyl, cyclobutinyl, or phenyl; each R 5 is independently R 4, C 1-4 alkyl, C 3-6 cycloalkyl, or C 1-4 alkyl optionally substituted with 1 or more R 4; each R 6 is independently halo, OH, -NH 2, -NHR 3, -N(R 3 R 3), -COOH, -COOR 3, - NHCO-R 3; each R 6 is independently C 1-4 alkyl or H, or two R 6 taken together with the nitrogen atom to which they are bound form a 4, 5, or 6 membered saturated heterocyclic ring containing 0 or 1 additional heteroatoms where such additional heteroatom is O or N wherein such heterocycle is optionally substituted with -OH, - NH 2, -N(R 3 R 3), n-hydroxy C 1-4 alkyl, -(CH 2) m -COOH, -(CH 2) m -COOR 3; X is NR'R" or -OR"'; R' is H, C 1-4 alkyl, n-hydroxy C 1-4 alkyl, -SO 2 -R 3, or -CO-R 3; R" is H, -SO 2 -R 5, C 1-4 alkyl optionally substituted with 1 or more R 4, or a ring moiety optionally substituted with R 6 wherein such ring moiety is piperidinyl, cyclohexyl, morpholinyl, thiazolyl, pyrazolyl, pyrrolidinyl, imidazolyl, or phenyl; R'" is H, C 1-4 alkyl, or -CO-R 3 each R 4 is independently H, halo, OH, oxo, =NH, NH 2, -COOH, F, -NHR 3, - N(R 7 R 7),-SO 2 -R 3, -SO 2 -N(R 7 R 7), -N(R 3)-SO 2 -R 3, -COOR 3, -OCO-R 3, -CO-N(R 7 R 7), -N(R 3)-COR 3, C 1-3 alkyl, C 1-3 alkoxy, and a ring moiety optionally substituted with R 6 wherein such ring moiety is piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyrazolyl, imidazolyl, benzimidazolyl, azetidinyl, cyclobutinyl, or phenyl; each R 5 is independently R 4, C 1-4 alkyl, C 3-6 cycloalkyl, or C 1-4 alkyl optionally substituted with 1 or more R 4; each R 6 is independently halo, OH, -NH 2, -NHR 3, -N(R 3 R 3), -COOH, -COOR 3, - NHCO-R 3; each R 6 is independently C 1-4 alkyl or H, or two R 6 taken together with the nitrogen atom to which they are bound form a 4, 5, or 6 membered saturated heterocyclic ring containing 0 or 1 additional heteroatoms where such additional heteroatom is O or N wherein such heterocycle is optionally substituted with -OH, - NH 2, -N(R 3 R 3), n-hydroxy C 1-4 alkyl, -(CH 2) m -COOH, -(CH 2) m -COOR 3; each m is independently 0, 1, 2, or 3,